Jenny J Lin1, Nicole Ezer2, Keith Sigel2, Grace Mhango2, Juan P Wisnivesky3. 1. Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1087, New York, NY 10029, USA. Electronic address: jenny.lin@mssm.edu. 2. Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1087, New York, NY 10029, USA. 3. Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1087, New York, NY 10029, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
Abstract
OBJECTIVES: Prior studies have shown an anticancer effect of statins in patients with certain malignancies. However, it is unclear whether statins have a mortality benefit in lung cancer. We compared survival of patients with stage IV non-small cell lung cancer (NSCLC) receiving vs. not receiving statins prior to diagnosis. METHODS: Using data from the Surveillance, Epidemiology and End Results registry linked to Medicare claims, we identified 5118 patients >65 years of age diagnosed with stage IV NSCLC between 2007 and 2009. We used propensity score methods to assess the association of statin use with overall and lung cancer-specific survival while controlling for measured confounders. RESULTS: Overall, 27% of patients were on statins at time of lung cancer diagnosis. Median survival in the statin group was 7 months, compared to 4 months in patients not treated with statins (p<0.001). Propensity score analyses found that statin use was associated with improvement in overall (hazard ratio [HR]: 0.76, 95% confidence interval [CI]: 0.73-0.79) and lung cancer-specific survival (HR: 0.77, 95% CI: 0.73-0.81), after controlling for baseline patient characteristics, cancer characteristics, staging work-up and chemotherapy use. CONCLUSIONS: Statin use is associated with improved survival among patients with stage IV NSCLC suggesting a potential anticancer effect. Further research should evaluate plausible biological mechanisms as well as test the effect of statins in prospective clinical trials.
OBJECTIVES: Prior studies have shown an anticancer effect of statins in patients with certain malignancies. However, it is unclear whether statins have a mortality benefit in lung cancer. We compared survival of patients with stage IV non-small cell lung cancer (NSCLC) receiving vs. not receiving statins prior to diagnosis. METHODS: Using data from the Surveillance, Epidemiology and End Results registry linked to Medicare claims, we identified 5118 patients >65 years of age diagnosed with stage IV NSCLC between 2007 and 2009. We used propensity score methods to assess the association of statin use with overall and lung cancer-specific survival while controlling for measured confounders. RESULTS: Overall, 27% of patients were on statins at time of lung cancer diagnosis. Median survival in the statin group was 7 months, compared to 4 months in patients not treated with statins (p<0.001). Propensity score analyses found that statin use was associated with improvement in overall (hazard ratio [HR]: 0.76, 95% confidence interval [CI]: 0.73-0.79) and lung cancer-specific survival (HR: 0.77, 95% CI: 0.73-0.81), after controlling for baseline patient characteristics, cancer characteristics, staging work-up and chemotherapy use. CONCLUSIONS: Statin use is associated with improved survival among patients with stage IV NSCLC suggesting a potential anticancer effect. Further research should evaluate plausible biological mechanisms as well as test the effect of statins in prospective clinical trials.
Authors: Ji-Youn Han; Soo-Hyun Lee; Nam Jin Yoo; Lee Suk Hyung; Yoon Joo Moon; Tak Yun; Heung Tae Kim; Jin Soo Lee Journal: Clin Cancer Res Date: 2011-03-15 Impact factor: 12.531
Authors: Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag Journal: Ann Epidemiol Date: 2007-05-25 Impact factor: 3.797
Authors: Joan L Warren; Linda C Harlan; Angela Fahey; Beth A Virnig; Jean L Freeman; Carrie N Klabunde; Gregory S Cooper; Kevin B Knopf Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Frances K Turrell; Emma M Kerr; Meiling Gao; Hannah Thorpe; Gary J Doherty; Jake Cridge; David Shorthouse; Alyson Speed; Shamith Samarajiwa; Benjamin A Hall; Meryl Griffiths; Carla P Martins Journal: Genes Dev Date: 2017-08-08 Impact factor: 11.361
Authors: Zoe Hall; Catherine H Wilson; Deborah L Burkhart; Tom Ashmore; Gerard I Evan; Julian L Griffin Journal: J Lipid Res Date: 2020-08-04 Impact factor: 5.922
Authors: Ye Sel Kim; Moo-Seok Park; Jun-Hwa Lee; Jong-Won Chung; Mi Ji Lee; Chi Kyung Kim; Jin-Man Jung; Kyungmi Oh; Oh Young Bang; Geong-Moon Kim; Ji-Mi Choi; Juneyoung Lee; Chin Sang Chung; Kwang Ho Lee; Woo-Keun Seo Journal: Front Neurol Date: 2018-04-24 Impact factor: 4.003